In vivo measurement of [11C]verapamil kinetics in human tissues

Eur J Clin Pharmacol. 2001 Jan-Feb;56(11):827-9. doi: 10.1007/s002280000253.

Abstract

Objective: To evaluate [11C]verapamil kinetics in humans.

Methods: After intravenous injection of [11C]verapamil (370 MBq, specific activity >1,600 GBq/mmol), kinetics were evaluated in five cancer patients using positron emission tomography (PET).

Results: One hour after injection, accumulation of [11C] in lungs, heart and tumour was 43.0%, 1.3% and 0.9% of the injected verapamil dose, respectively. Half-lives of [11C]verapamil in these tissues were 46.2 min, 73.8 min and 23.7 min, respectively.

Conclusions: Intravenously administered [11C] was mainly extracted by the lungs. Transport of a [11C]verapamil bolus out of solid tumour tissue is relatively fast.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Calcium Channel Blockers / administration & dosage
  • Calcium Channel Blockers / blood
  • Calcium Channel Blockers / pharmacokinetics*
  • Female
  • Half-Life
  • Humans
  • Injections, Intravenous
  • Male
  • Middle Aged
  • Neoplasms / metabolism*
  • Tissue Distribution
  • Tomography, Emission-Computed
  • Verapamil / administration & dosage
  • Verapamil / blood
  • Verapamil / pharmacokinetics*

Substances

  • Calcium Channel Blockers
  • Verapamil